Journal of Medical Oncology and Therapeutics

All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.
Reach Us +44-7360-538437

About The Journal Open Access

Journal of Medical Oncology and Therapeutics

Oncology is a vast and well researched subject in medical world. Analysing the medical part of it is assumed to be pivotal in curing many cancer and related diseases. As per the definition, Medical oncology manages the utilization of systemic medications going for cancer cell executing and control. The branch of Medical Oncology in the majority of the research centres, hospitals, institutes has master advisors with enthusiasm for the administration of solid tumours and additionally paediatric cancers. The medicinal oncology group is involving specialists in the utilization of systemic treatment including chemotherapy, endocrine therapy, and additionally the most recent organic and focused on medications for solid tumours.

Medical Oncology and Therapeutics provides optimum platform where researchers from all over world can submit their work to it. Journal of Medical Oncology and Therapeutics is a famed international journal having an impeccable Reviewer and Editorial Board.

This multidisciplinary open access journal provides the chance to researches to disseminate the work in the form of original research article, review article, case reports, short communication etc.

Aim and Scope

Medical Oncology and Therapeutics conveys and aims the aftereffects of clinical and experimental examination in oncology and haematology, especially experimental therapeutics inside of the fields of immunotherapy and chemotherapy. It additionally gives cutting edge audits on clinical and experimental treatments. Subjects covered include incorporate immune biology, pathogenesis, and treatment of malignant tumours.

Journal of Medical Oncology and Therapeutics is a scientific open access journal that deals and describes the developmental activities conducted in the vast field of Oncological research. This journal encompasses the study related to Breast Cancer, Cell Line, Prostate Cancer, Tumour Cells, Genetics, Radiation Therapy, Lung Cancer, Prognostic Factor, Colorectal Cancer, Non-Small Cell Lung Cancer, Ovarian Cancer, Cell Cycle, Gene Expression, Cell Proliferation, Breast Carcinoma, Squamous Cell Carcinoma, Transcription Factor, case-control study Cell Death, Monoclonal Antibody, Hepatocellular Carcinoma disciplines.

Submission of important articles containing advanced research output aiding in forwarding the subject are most welcome. The wide scope of the journal will aid in contributing a great measure of scientific information related to the advances in towards better healthcare.

The Journal is using Editor Manager System for easy online tracking and managing of the manuscript processing. Each article undergoes a peer review process under the aegis of an assigned Editor. To be acceptable for publication, an article should be positively considered by two individual reviewers followed by the Editor’s consent.

You may send the article online at or via mail at [email protected] or [email protected]

Fast Editorial Execution and Review Process (FEE-Review Process)

This journal is participating in the Fast Editorial Execution and Review Process (FEE-Review Process) with an additional prepayment of $99 apart from the regular article processing fee. Fast Editorial Execution and Review Process is a special service for the article that enables it to get a faster response in the pre-review stage from the handling editor as well as a review from the reviewer. An author can get a faster response of pre-review maximum in 3 days since submission, and a review process by the reviewer maximum in 5 days, followed by revision/publication in 2 days. If the article gets notified for revision by the handling editor, then it will take another 5 days for external review by the previous reviewer or alternative reviewer.

Acceptance of manuscripts is driven entirely by handling editorial team considerations and independent peer-review, ensuring the highest standards are maintained no matter the route to regular peer-reviewed publication or a fast editorial review process. The handling editor and the article contributor are responsible for adhering to scientific standards. The article FEE-Review process of $99 will not be refunded even if the article is rejected or withdrawn for publication.

The corresponding author or institution/organization is responsible for making the manuscript FEE-Review Process payment. The additional FEE-Review Process payment covers the fast review processing and quick editorial decisions, and regular article publication covers the preparation in various formats for online publication, securing full-text inclusion in a number of permanent archives like HTML, XML, and PDF, and feeding to different indexing agencies.


Articles published in Journal of Medical Oncology and Therapeutics have been cited by esteemed scholars and scientists all around the world. Journal of Medical Oncology and Therapeutics has got H-index 4 , which means every article in Journal of Medical Oncology and Therapeutics has got 4 average citations.

Please submit your manuscript to
[email protected]

Just Published Articles

Opinion Article December 24, 2021


J Med Oncl Ther: 6(6): 44-44

Acknowledgment and toxicological viewpoints of pulmonary carcinoma.

Ahmed Ibrahim

Perspective December 24, 2021


J Med Oncl Ther: 6(6): 43-43

Understanding radiation treatment and brachytherapy from an oncologist point of view.

Olivia Garcia

Commentary December 24, 2021


J Med Oncl Ther: 6(6): 42-42

Clarification, complications and side impacts of prostate cancer patients experiencing cryosurgery.

Megumi Suzuki

Mini Review December 24, 2021


J Med Oncl Ther: 6(6): 40-41

The oncologists guide to synoptic reporting: A primer, terminology: Safety issues and uniformity.

Alexa Nora

Short Communication December 24, 2021


J Med Oncl Ther: 6(6): 38-39

A brief note on Gene mutations of hereditary breast ovarian cancer.

Diallo Kellan

Relevant Topics

Get the App